Researchers set to begin new Covid-19 vaccine trial for 12-16 year olds

Researchers in Southampton are to begin a new COVID-19 vaccine trial looking at different vaccination schedules for young people.

The Com-COV 3 study will be based at the University Hospital Southampton NHS Foundation Trust, and will test different COVID-19 vaccines used as a second dose in young people aged 12 to 16.

Researchers are looking for participants to take part in the trial.

It is open to 12-to-16 year olds who have already received one dose of the Pfizer-BioNTech COVID-19 vaccine through the NHS, as well as those who are yet to receive a COVID-19 vaccine.

Participants will receive two COVID-19 vaccine doses in the study, where the first dose will be the Pfizer vaccine.

Alternatively, those who have already received a dose of the Pfizer COVID-19 vaccine through the NHS can be enrolled at the time of their second dose.

University Hospital Southampton NHS Foundation Trust Credit: Andrew Matthews/PA Wire

All participants will be randomly allocated at the time of the second dose to receive either a full dose or half dose of the Pfizer-BioNTech vaccine, a full dose of the Novavax vaccine or a half dose of the Moderna vaccine.

The study, which will recruit 360 volunteers across the UK, hopes to report initial results by December.

Dr Katrina Cathie, Consultant in General Paediatrics and Paediatric Research at University Hospital Southampton and local lead for the trial, said: "We are really pleased to be able to offer local adolescents the opportunity to take part in this trial, looking at different COVID-19 vaccines used as a second dose.

"Currently healthy 12-17 year olds are being offered a single COVID-19 vaccine in the NHS. The results from this trial are expected around Christmas and will directly inform decisions about the roll-out of a second dose of a COVID-19 vaccine in this age group in the spring."

Those interested in taking part in the study can sign up here.